TY - JOUR
T1 - The WHO Mental Health Gap Action Programme for mental, neurological, and substance use conditions
T2 - the new and updated guideline recommendations
AU - Brohan, Elaine
AU - Chowdhary, Neerja
AU - Dua, Tarun
AU - Barbui, Corrado
AU - Thornicroft, Graham
AU - Kestel, Dévora
AU - WHO mhGAP guideline team
AU - Ali, Amza
AU - Assanangkornchai, Sawitri
AU - Brodaty, Henry
AU - Carli, Vladimir
AU - El Chammay, Rabih
AU - Chang, Odille
AU - Collins, Pamela Y.
AU - Cuijpers, Pim
AU - Dowrick, Christopher
AU - Eaton, Julian
AU - Ferri, Cleusa P.
AU - Fortes, Sandra
AU - Hengartner, Michael P.
AU - Humayun, Asma
AU - Jette, Nathalie
AU - de Vries, Petrus J.
AU - Medina-Mora, Maria Elena
AU - Murthy, Pratima
AU - Nadera, Dinah
AU - Newton, Charles
AU - Njenga, Michael
AU - Omigbodun, Olayinka
AU - Rahimi-Movaghar, Afarin
AU - Rahman, Atif
AU - Fortunato dos Santos, Palmira
AU - Saxena, Shekhar
AU - Vijayakumar, Lakshmi
AU - Wang, Huali
AU - Wattanavitukul, Pichayanan
AU - Yewnetu, Enat
AU - Carswell, Ken
AU - Chatterjee, Sudipto
AU - Fatima, Batool
AU - Fleischmann, Alexandra
AU - Gray, Brandon
AU - Hanlon, Charlotte
AU - Hanna, Fahmy
AU - Krupchanka, Dzmitry
AU - Malik, Aiysha
AU - van Ommeren, Mark
AU - Poznyak, Vladimir
AU - Seeher, Katrin
AU - Servili, Chiara
AU - Weissbecker, Inka
N1 - Funding Information: We thank the Topic Expert Group members, Evidence Review and Synthesis Team members, External Review Group members, and other members of the WHO Department of Mental Health and Substance Use for their contributions to the guideline update. Financial support for the development of this guideline was provided by the Norwegian Programme for Capacity Development in Higher Education and Research for Development, the Swiss Agency for Development and Cooperation, and the Wellcome Trust. Funding Information: We thank the Topic Expert Group members, Evidence Review and Synthesis Team members, External Review Group members, and other members of the WHO Department of Mental Health and Substance Use for their contributions to the guideline update. Financial support for the development of this guideline was provided by the Norwegian Programme for Capacity Development in Higher Education and Research for Development, the Swiss Agency for Development and Cooperation, and the Wellcome Trust. Publisher Copyright: © 2023 Elsevier Ltd
PY - 2023/11/16
Y1 - 2023/11/16
N2 - The WHO Mental Health Gap Action Programme (mhGAP) guideline update reflects 15 years of investment in reducing the treatment gap and scaling up care for people with mental, neurological, and substance use (MNS) conditions. It was produced by a guideline development group and steering group, with support from topic experts, using quantitative and qualitative evidence and a systematic review of use of mhGAP. 90 recommendations from the 2015 guideline update were validated and endorsed for use in their current format. These are joined by 30 revised recommendations and 18 new recommendations, including a new module on anxiety. Psychological interventions are emphasised as treatments and digitally delivered interventions feature across many modules, as well as updated recommendations for psychotropic medicines. Research gaps identified include the need for evidence from low-resource settings and on the views of people with lived experience of MNS conditions. The revised recommendations ensure that mhGAP continues to offer high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low-income and middle-income countries in providing care to individuals with MNS conditions.
AB - The WHO Mental Health Gap Action Programme (mhGAP) guideline update reflects 15 years of investment in reducing the treatment gap and scaling up care for people with mental, neurological, and substance use (MNS) conditions. It was produced by a guideline development group and steering group, with support from topic experts, using quantitative and qualitative evidence and a systematic review of use of mhGAP. 90 recommendations from the 2015 guideline update were validated and endorsed for use in their current format. These are joined by 30 revised recommendations and 18 new recommendations, including a new module on anxiety. Psychological interventions are emphasised as treatments and digitally delivered interventions feature across many modules, as well as updated recommendations for psychotropic medicines. Research gaps identified include the need for evidence from low-resource settings and on the views of people with lived experience of MNS conditions. The revised recommendations ensure that mhGAP continues to offer high-quality, timely, transparent, and evidence-based guidance to support non-specialist health workers in low-income and middle-income countries in providing care to individuals with MNS conditions.
U2 - 10.1016/S2215-0366(23)00370-X
DO - 10.1016/S2215-0366(23)00370-X
M3 - Article
SN - 2215-0366
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
ER -